Ovid Therapeutics downgraded by Oppenheimer
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Outperform → Perform | Oppenheimer | |
| 4/30/2024 | $9.00 | Buy | B. Riley Securities |
| 4/29/2024 | $9.00 | Buy | H.C. Wainwright |
| 4/5/2024 | $8.00 | Outperform | Wedbush |
| 12/21/2023 | $11.00 | Buy | BTIG Research |
| 10/13/2023 | $8.00 | Outperform | Oppenheimer |
| 8/25/2021 | $4.50 → $4.00 | Neutral | Citigroup |
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberger will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-endCash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expected to support currently planned operations and development programs into the 2H of 2026 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da